Hikma delivers solid mid-year performance

AMMAN — Hikma Pharmaceuticals announced Wednesday in a press statement that group revenue reached $709 million during the six months ended June 30, 2015, in line with the first half of 2014.

"The full year 2015 group revenue guidance maintained at around 6 per cent growth in constant currency, or 2 pre cent on a reported basis," it said Hikma indicated in the press release that it launched 40 new products and received 118 product approvals across all countries and markets.

"Branded revenue rose by 16 per cent in constant currency or 9 per cent on a reported basis, resulting from a strong performance in the countries of the Gulf Cooperation Council and Algeria, Hikma’s two largest MENA markets," the company said.

In line with expectations, following the extremely strong performance in the prior year, global Injectables revenue increased 3 per cent on a constant currency basis, due to sustaining strong sales across the broad portfolio and have continued to be successful in capturing specific market opportunities.

The successful integration of Bedford is delivering new approvals for US Injectables as Hikma continues to enhance its global injectables product portfolio.